Galenica: Vifor Fresenius Medical Care Renal Pharma to expand its business activities Donnerstag, 28. Mai 2015 - 07:00
Thursday, 28 May 2015, ↓ directly to download
Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe
Galenica and Fresenius Medical Care further develop their common company Vifor Fresenius Medical Care Renal Pharma. The company, which specialises in nephrology medicines, is to expand its product portfolio and substantially further develop sales and marketing organisation for nephrology medicines in Europe.
Vifor Fresenius Medical Care Renal Pharma, which specialises in nephrology medicines, is expanding its product portfolio. In addition to the iron replacement products Ferinject® and Venofer® for use in nephrology indications as well as the phosphate binder Velphoro®, the company will acquire nephrology medicines commercialised by Fresenius Medical Care, including the phosphate binders Osvaren® and Phosphosorb®. The transfer of the marketing rights is to be completed by the end of 2015. The parties have agreed not to disclose the financial aspects of the agreement.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).